-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...

-The Business Standard Patients' lobbies cheer ruling on anti-cancer drug Glivec, as affordability and access to life-saving drugs get a leg-up Though the India office here of Swiss pharma giant Novartis wore a gloomy look following the Supreme Court rejection of its Glivec patent application, Indian pharmaceutical companies and patients' associations are in celebration mood. D G Shah, secretary general, The Indian Pharmaceutical Alliance (IPA), comprising leading research-based Indian pharma companies, said,...

-Reuters India's top court imposed a fine of Rs 100 crore ($18.40 million) on Sterlite Industries for polluting environment through its copper smelting plant in Tamil Nadu. The case is unrelated to a separate order that has shut the Tuticorin plant, India's largest, since last week following complaints of a gas leak. Despite the fine, the Supreme Court overruled an earlier order from the Madras High Court to shut down the plant over...

-PTI The Supreme Court on Tuesday asked Sterlite Industries, a subsidiary of U.K.-based Vedanta Group, to pay Rs. 100 crore as compensation for polluting environment through its copper smelting plant in Tamil Nadu but refused to direct its closure. A bench headed by Justice A.K. Patnaik said that the environment has been polluted for a long time due to the discharge from the plant of the multinational company and it has...

-The Hindu   Supreme Court rejects Novartis' plea for patent; green signal for cheaper generic drugs In a ruling that will help patients continue to buy several life-saving medicines as generic drugs, the Supreme Court on Monday held that the modification of a well known cancer-fighting drug is not a patentable new invention. The judgment allows suppliers to continue making generic copies of Swiss firm Novartis' Glivec or Gleevec, which has been shown to...